R H A Verhoeven
Overview
Explore the profile of R H A Verhoeven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
794
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Kleef J, Dijksterhuis W, van den Boorn H, Prins M, Verhoeven R, Gisbertz S, et al.
Gastric Cancer
. 2021 Jul;
24(6):1203-1212.
PMID: 34251543
Background: Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover,...
12.
Meijer L, Verhoeven R, de Hingh I, van de Wouw A, van Laarhoven H, Lemmens V, et al.
Clin Exp Metastasis
. 2021 Jan;
38(2):231-238.
PMID: 33515369
Patients with carcinoma of unknown primary (CUP) present with metastatic disease without an identified primary tumour. The unknown site of origin makes the diagnostic work-up and treatment challenging. Since little...
13.
Ende T, de Clercq N, van Berge Henegouwen M, Gisbertz S, Geijsen E, Verhoeven R, et al.
Clin Cancer Res
. 2021 Jan;
27(12):3351-3359.
PMID: 33504550
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death...
14.
Koemans W, Luijten J, van der Kaaij R, Grootscholten C, Snaebjornsson P, Verhoeven R, et al.
Cancer Epidemiol
. 2020 Oct;
69:101846.
PMID: 33126042
Introduction: The Lauren classification of gastric adenocarcinoma describes three histological subtypes, the intestinal, the diffuse and the mixed type carcinoma. The metastatic pattern of gastric adenocarcinoma by histological subtype has...
15.
van Kleef J, van den Boorn H, Verhoeven R, Vanschoenbeek K, Abu-Hanna A, Zwinderman A, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32244310
The SOURCE prediction model predicts individualised survival conditional on various treatments for patients with metastatic oesophageal or gastric cancer. The aim of this study was to validate SOURCE in an...
16.
Koeter T, Elferink M, Verhoeven R, Zimmerman D, Wasowicz D, Verheij M, et al.
Radiother Oncol
. 2020 Feb;
145:162-171.
PMID: 32007760
Introduction: The aim of this study was to examine the hospital variation in neoadjuvant treatment of rectal cancer according to the different risk groups (low-, intermediate- and high-risk) and evaluate...
17.
Walraven J, Desar I, Hoeven van der J, Aben K, Hillegersberg van R, Rasch C, et al.
Eur J Cancer
. 2019 Sep;
121:85-93.
PMID: 31563730
Introduction: For optimal oncological care, it is recommended to discuss every patient with cancer in a multidisciplinary team meeting (MDTM). This is a time consuming and expensive practice, leading to...
18.
Mokadem I, Dijksterhuis W, van Putten M, Heuthorst L, de Vos-Geelen J, Haj Mohammad N, et al.
Gastric Cancer
. 2019 Apr;
22(6):1263-1273.
PMID: 30949777
Background: In most western European countries perioperative chemotherapy is a part of standard curative treatment for gastric cancer. Nevertheless, recurrence rates remain high after multimodality treatment. This study examines patterns...
19.
Claassen Y, Bastiaannet E, Hartgrink H, Dikken J, de Steur W, Slingerland M, et al.
BJS Open
. 2019 Feb;
3(1):56-61.
PMID: 30734016
Background: In the randomized Asian REGATTA trial, no survival benefit was shown for additional gastrectomy over chemotherapy alone in patients with advanced gastric cancer with a single incurable factor, thereby...
20.
Faiz Z, van Putten M, Verhoeven R, van Sandick J, Nieuwenhuijzen G, van der Sangen M, et al.
Ann Surg Oncol
. 2019 Feb;
26(4):986-995.
PMID: 30719634
Purpose: This study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery. Methods: In this population-based...